Literature DB >> 19318562

Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.

Jerome C Nwachukwu1, Paolo Mita, Rachel Ruoff, Susan Ha, Qianben Wang, S Joseph Huang, Samir S Taneja, Myles Brown, William L Gerald, Michael J Garabedian, Susan K Logan.   

Abstract

The androgen receptor (AR) directs diverse biological processes through interaction with coregulators such as AR trapped clone-27 (ART-27). Our results show that ART-27 is recruited to AR-binding sites by chromatin immunoprecipitation analysis. In addition, the effect of ART-27 on genome-wide transcription was examined. The studies indicate that loss of ART-27 enhances expression of many androgen-regulated genes, suggesting that ART-27 inhibits gene expression. Surprisingly, classes of genes that are up-regulated upon ART-27 depletion include regulators of DNA damage checkpoint and cell cycle progression, suggesting that ART-27 functions to keep expression levels of these genes low. Consistent with this idea, stable reduction of ART-27 by short-hairpin RNA enhances LNCaP cell proliferation compared with control cells. The effect of ART-27 loss was also examined in response to the antiandrogen bicalutamide. Unexpectedly, cells treated with ART-27 siRNA no longer exhibited gene repression in response to bicalutamide. To examine ART-27 loss in prostate cancer progression, immunohistochemistry was conducted on a tissue array containing samples from primary tumors of individuals who were clinically followed and later shown to have either recurrent or nonrecurrent disease. Comparison of ART-27 and AR staining indicated that nuclear ART-27 expression was lost in the majority of AR-positive recurrent prostate cancers. Our studies show that reduction of ART-27 protein levels in prostate cancer may facilitate antiandrogen-resistant disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318562      PMCID: PMC2702238          DOI: 10.1158/0008-5472.CAN-08-3738

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Molecular genetics of prostate cancer.

Authors:  C Abate-Shen; M M Shen
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

2.  MYC recruits the TIP60 histone acetyltransferase complex to chromatin.

Authors:  Scott R Frank; Tiziana Parisi; Stefan Taubert; Paula Fernandez; Miriam Fuchs; Ho-Man Chan; David M Livingston; Bruno Amati
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

3.  First-trimester trophoblast cell model gene response to hypoxia.

Authors:  Nikki Koklanaris; Jerome C Nwachukwu; S Joseph Huang; Seth Guller; Ksenia Karpisheva; Michael Garabedian; Men-Jean Lee
Journal:  Am J Obstet Gynecol       Date:  2006-03       Impact factor: 8.661

4.  c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation.

Authors:  S-Y Chen; C Cai; C J Fisher; Z Zheng; J Omwancha; C-L Hsieh; L Shemshedini
Journal:  Oncogene       Date:  2006-05-29       Impact factor: 9.867

5.  TIP49b, a regulator of activating transcription factor 2 response to stress and DNA damage.

Authors:  S G Cho; A Bhoumik; L Broday; V Ivanov; B Rosenstein; Z Ronai
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 6.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Authors:  Howard I Scher; Charles L Sawyers
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

7.  Identification and characterization of ART-27, a novel coactivator for the androgen receptor N terminus.

Authors:  Steven M Markus; Samir S Taneja; Susan K Logan; Wenhui Li; Susan Ha; Adam B Hittelman; Inez Rogatsky; Michael J Garabedian
Journal:  Mol Biol Cell       Date:  2002-02       Impact factor: 4.138

8.  Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.

Authors:  Myles C Hodgson; Inna Astapova; Anthony N Hollenberg; Steven P Balk
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  UXT interacts with the transcriptional repressor protein EVI1 and suppresses cell transformation.

Authors:  Roger McGilvray; Mark Walker; Chris Bartholomew
Journal:  FEBS J       Date:  2007-07-16       Impact factor: 5.542

View more
  13 in total

1.  Regulation of androgen receptor-mediated transcription by RPB5 binding protein URI/RMP.

Authors:  Paolo Mita; Jeffrey N Savas; Nabil Djouder; John R Yates; Susan Ha; Rachel Ruoff; Eric D Schafler; Jerome C Nwachukwu; Naoko Tanese; Nicholas J Cowan; Jiri Zavadil; Michael J Garabedian; Susan K Logan
Journal:  Mol Cell Biol       Date:  2011-07-05       Impact factor: 4.272

Review 2.  Androgen receptor co-activators in the regulation of cellular events in prostate cancer.

Authors:  Zoran Culig; Frédéric R Santer
Journal:  World J Urol       Date:  2011-11-22       Impact factor: 4.226

Review 3.  Androgen receptor coactivators that inhibit prostate cancer growth.

Authors:  Garrett Daniels; Ruchi Jha; Ying Shen; Susan K Logan; Peng Lee
Journal:  Am J Clin Exp Urol       Date:  2014-04-05

4.  Ecotropic viral integration site 1, a novel oncogene in prostate cancer.

Authors:  A Queisser; S Hagedorn; H Wang; T Schaefer; M Konantz; S Alavi; M Deng; W Vogel; A von Mässenhausen; G Kristiansen; S Duensing; J Kirfel; C Lengerke; S Perner
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

5.  UXT in Sertoli cells is required for blood-testis barrier integrity†.

Authors:  Phillip A Thomas; Eric D Schafler; Sophie E Ruff; Maud Voisin; Susan Ha; Susan K Logan
Journal:  Biol Reprod       Date:  2020-10-05       Impact factor: 4.285

6.  TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.

Authors:  Garrett Daniels; Yirong Li; Lan Lin Gellert; Albert Zhou; Jonathan Melamed; Xinyu Wu; Xinming Zhang; David Zhang; Daniel Meruelo; Susan K Logan; Ross Basch; Peng Lee
Journal:  Endocr Relat Cancer       Date:  2014-01-16       Impact factor: 5.678

7.  Functional domains of androgen receptor coactivator p44/Mep50/WDR77and its interaction with Smad1.

Authors:  Yirong Li; Liantian Tian; Martin Ligr; Garrett Daniels; Yi Peng; Xinyu Wu; Mandeep Singh; Jianjun Wei; Yongzhao Shao; Herbert Lepor; Ruliang Xu; Zhijie Chang; Zhengxin Wang; Peng Lee
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

8.  Analysis of URI nuclear interaction with RPB5 and components of the R2TP/prefoldin-like complex.

Authors:  Paolo Mita; Jeffrey N Savas; Susan Ha; Nabil Djouder; John R Yates; Susan K Logan
Journal:  PLoS One       Date:  2013-05-08       Impact factor: 3.240

9.  Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.

Authors:  S Ha; N J Iqbal; P Mita; R Ruoff; W L Gerald; H Lepor; S S Taneja; P Lee; J Melamed; M J Garabedian; S K Logan
Journal:  Oncogene       Date:  2012-09-17       Impact factor: 9.867

10.  Art27 interacts with GATA4, FOG2 and NKX2.5 and is a novel co-repressor of cardiac genes.

Authors:  Daniel R Carter; Andrew D Buckle; Kumiko Tanaka; Jose Perdomo; Beng H Chong
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.